SI-BONE, Inc. (NASDAQ:SIBN) Receives Average Recommendation of “Buy” from Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have been assigned an average rating of “Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the stock in the last year is $23.00.

SIBN has been the subject of a number of research analyst reports. Truist Financial increased their price target on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Morgan Stanley reduced their price target on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of SI-BONE in a research report on Wednesday.

SI-BONE Price Performance

SIBN stock opened at $12.56 on Friday. SI-BONE has a 52-week low of $11.70 and a 52-week high of $21.70. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The stock has a market cap of $526.74 million, a price-to-earnings ratio of -13.65 and a beta of 1.22. The business has a fifty day moving average of $13.72 and a two-hundred day moving average of $14.22.

Insider Buying and Selling

In other news, CEO Laura Francis sold 10,048 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.58, for a total value of $126,403.84. Following the sale, the chief executive officer now directly owns 482,875 shares in the company, valued at approximately $6,074,567.50. This trade represents a 2.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anthony J. Recupero sold 3,305 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares of the company’s stock, valued at $3,169,734.96. The trade was a 1.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,093 shares of company stock valued at $299,558 in the last ninety days. Company insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On SI-BONE

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in SI-BONE by 1.8% in the first quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock valued at $40,328,000 after acquiring an additional 43,670 shares in the last quarter. Bessemer Group Inc. increased its position in shares of SI-BONE by 79.8% in the 1st quarter. Bessemer Group Inc. now owns 37,859 shares of the company’s stock valued at $620,000 after purchasing an additional 16,800 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of SI-BONE by 7.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock valued at $336,000 after purchasing an additional 1,372 shares in the last quarter. Bellevue Group AG lifted its position in shares of SI-BONE by 810.5% during the 1st quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock worth $18,661,000 after purchasing an additional 1,014,756 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC grew its stake in shares of SI-BONE by 13.8% during the first quarter. Silvercrest Asset Management Group LLC now owns 1,060,937 shares of the company’s stock worth $17,368,000 after purchasing an additional 128,702 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.